 As someone who has spent a lot of time looking at these trials, it is important to recognize that these trials specifically involve populations at high risk for cardiovascular disease. Whether these findings can be generalized to the general population of people with diabetes, we don't have enough evidence to make that statement. I think because this was meant to look at the outcomes, perhaps those nuances of the populations, which are important for applicability to a real world of care, may not have been detailed.